The G8 tool identifies vulnerable older cancer patients in 5 minutes — here is the complete review of its scoring system, 85–87% sensitivity, and how it guides treatment decisions.
By Dr. Elena Marsh, Health Technology Correspondent
Published: November 18, 2026 · 9 min read
The G8 is an 8-item validated screening questionnaire (scores 0–17) for identifying geriatric vulnerability in older cancer patients. A score ≤14 indicates positive screening and referral for comprehensive geriatric assessment (CGA). Pooled sensitivity is 85–87%, AUC 0.80–0.82. ESMO recommends it for all cancer patients aged 70+ starting treatment. CGA-guided treatment modifications reduce grade 3–4 chemotherapy toxicity by 24% (Lancet Oncology, 2017).
Cancer disproportionately affects older adults: approximately 60% of new cancer diagnoses in the US occur in patients aged 65 and over, and 70% of cancer-related deaths. As oncology treatment has become more effective, the clinical challenge has shifted — from 'can we treat this cancer?' to 'can this patient tolerate the treatment required?' This question is poorly answered by conventional oncology assessment tools.
ECOG performance status — the standard clinical measure of functional fitness for chemotherapy — has significant limitations in older patients. Two patients with identical ECOG PS 1 scores may have radically different underlying reserve: one may be an active 72-year-old with no comorbidities and normal cognition; another may be a frail 76-year-old with mild cognitive impairment, 4 kg of recent weight loss, and fall history. Standard oncology protocols would treat them identically; geriatric assessment would identify the vulnerability profile that predicts dramatically different treatment tolerance and outcomes.
| Item | Question | Score range |
|---|---|---|
| A | Has food intake declined in the last 3 months? | 0–2 |
| B | Weight loss over last 3 months | 0–3 |
| C | Mobility | 0–2 |
| E | Neuropsychological problems (dementia or depression) | 0–2 |
| F | Body mass index (BMI) | 0–3 |
| H | Taking more than 3 medications per day | 0–1 |
| P | Self-perception of health vs peers | 0–2 |
| Age | Age ≥80 scores 0; age <80 scores 1 | 0–1 |
Total score: 0–17. Score ≤14 = positive screen (refer for CGA). Score ≥15 = normal screen. Items use the same response format as the Mini Nutritional Assessment (MNA), from which G8 items B, C, E, F, and P are directly derived.
The clinical rationale for G8 screening is underpinned by several key evidence streams. The validation meta-analysis (JGO 2020, n=5,765) established the tool's psychometric properties: 85–87% sensitivity, 61–65% specificity, AUC 0.80–0.82. The ELCAPA study (Lancet Oncology 2017) provided the highest-quality evidence for clinical impact: 1,100 patients randomised to CGA-guided versus standard treatment showed a 24% reduction in grade 3–4 chemotherapy toxicity in the CGA arm — without compromising response rates. A 2022 systematic review of CGA in surgical oncology (Journal of Geriatric Oncology, 15 RCTs) found that prehabilitation guided by CGA findings reduced postoperative complications by 31% and length of stay by 1.8 days across colorectal, hepatobiliary, and urological cancer surgeries.
Deep Dive
Our comprehensive guide covers the science, protocols, and tools in detail — with FAQs answered by our research team.
Read the Full Guide →© 2026 QuanMed - All rights reserved